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Abstract
The aim of this study was to determine, through a genome-wide association study (GWAS), the genetic components
contributing to different clinical sub-phenotypes of systemic sclerosis (SSc). We considered limited (lcSSc) and diffuse
(dcSSc) cutaneous involvement, and the relationships with presence of the SSc-specific auto-antibodies, anti-centromere
(ACA), and anti-topoisomerase I (ATA). Four GWAS cohorts, comprising 2,296 SSc patients and 5,171 healthy controls, were
meta-analyzed looking for associations in the selected subgroups. Eighteen polymorphisms were further tested in nine
independent cohorts comprising an additional 3,175 SSc patients and 4,971 controls. Conditional analysis for associated
SNPs in the HLA region was performed to explore their independent association in antibody subgroups. Overall analysis
showed that non-HLA polymorphism rs11642873 in IRF8 gene to be associated at GWAS level with lcSSc (P=2.32610
212,
OR=0.75). Also, rs12540874 in GRB10 gene (P=1.27 6 10
26, OR=1.15) and rs11047102 in SOX5 gene (P=1.39610
27,
OR=1.36) showed a suggestive association with lcSSc and ACA subgroups respectively. In the HLA region, we observed
highly associated allelic combinations in the HLA-DQB1 locus with ACA (P=1.79610
261, OR=2.48), in the HLA-DPA1/B1 loci
with ATA (P=4.57610
276, OR=8.84), and in NOTCH4 with ACA P=8.84610
221, OR=0.55) and ATA (P=1.14610
28,
PLoS Genetics | www.plosgenetics.org 1 July 2011 | Volume 7 | Issue 7 | e1002178OR=0.54). We have identified three new non-HLA genes (IRF8, GRB10, and SOX5) associated with SSc clinical and auto-
antibody subgroups. Within the HLA region, HLA-DQB1, HLA-DPA1/B1, and NOTCH4 associations with SSc are likely confined
to specific auto-antibodies. These data emphasize the differential genetic components of subphenotypes of SSc.
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Introduction
Genetic factors play an essential role in scleroderma or systemic
sclerosis (SSc) etiology as in most complex autoimmune diseases
[1]. Multiple reports of well powered candidate gene association
and replication studies, together with the first genome-wide
association study (GWAS) in this disease have led to the
establishment of the Major histocompatibility complex (MHC),
STAT4, IRF5, BLK, BANK1, TNFSF4 and CD247 as SSc
susceptibility genes [2–15].
SSc is a clinically heterogeneous disease with a wide range of
clinical manifestations, ranging from mild skin fibrosis with
minimal internal organ disease to severe skin and organ
involvement, reflecting the three main pathological events that
characterize this disease: endothelial damage, fibrosis, and
autoimmune dysregulation [16]. SSc patients are classified into
two clinical subgroups based on the extent of skin involvement,
limited SSc (lcSSc) and diffuse SSc (dcSSc) that are associated with
different clinical complications and prognoses [17]. Another SSc
hallmark is the presence of disease specific and usually mutually
exclusive auto-antibodies that correlate both with the extent of skin
involvement and the various disease manifestations, such as
pulmonary fibrosis and renal crisis [18]. The most common are
DNA topoisomerase I (ATA), and anti-centromere antibodies
(CENP A and/or B proteins) [19]. Each of these auto-antibodies is
a marker for relatively distinct clinical subgroups of SSc, with anti-
centromere typically associated with limited cutaneous disease,
uncommon pulmonary fibrosis, late-onset pulmonary hyperten-
sion but generally an overall good prognosis, while ATA is a
marker for diffuse skin disease and clinically significant pulmonary
fibrosis with a resultant poorer prognosis.
It has been observed that certain SSc clinical features and the
presence of disease specific auto-antibodies vary in different
countries and ethnicities [20]. This fact supports the likelihood that
genetic factors may influence the different clinical features of the
disease and auto-antibody subsets [19]. Furthermore, the affected
members within multicase SSc families tend to be concordant for
SSc-specific auto-antibodies and HLA haplotypes, thus, providing
further evidence for a genetic basis for auto-antibody expression in
SSc [21]. Moreover, several studies have reported that certain SSc
genetic risk factors correlate with specific clinical subsets of the
disease or SSc-related auto-antibodies [4,12,22,23].
In this study, we aimed to identify novel genetic factors
associated with different SSc clinical and auto-antibody subsets
through a stratified re-analysis of results from a previous GWAS
from our group and validation in a large replication study.
Results
First, the genetic associations were tested in each of the four
subgroups considered for this study (lcSSc, dcSSc, ACA positive
and ATA positive) by the means of x2 tests in the GWAS data
(individuals from the United States, Spain, Germany and The
Netherlands), correcting the P values for the genomic inflation
factor l of each subgroup (Figures S1, S2, S3, S4 and Tables S1,
S2, S3, S4). We found a total of eighteen novel non-HLA loci
associated in these subgroups with a P value lower than 1610
25,
seven in the lcSSc subtype, five in the dcSSc subtype, two in ACA
positives and four in ATA positives. Next, we proceeded to
replicate these associations in nine independent cohorts (from US,
Spain, Germany, The Netherlands, Belgium, Italy, Sweden,
United Kingdom and Norway). The statistically significant results
observed in the replication step are shown in Table 1. The
complete set of data is shown in Tables S1, S2, S3 S4.
In addition, exhaustive analysis was performed in the HLA
region (megabases 28 to 34 in chromosome 6) with the GWAS
data in order to find specific subgroup associations in this region.
Due to the fact that most associations found herein in the MHC
region have been previously described, we did not perform a
replication phase of these findings. Instead, let these results be the
Systemic Sclerosis Novel Genetic Associations
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independent associations found within the MHC region have
almost exactly the same ORs in the four GWAS cohorts
separately, thus, replicating themselves.
Clinical Manifestations
In the lcSSc subtype, seven non-HLA novel loci were identified
as susceptibility markers in the GWAS data (Table S1 and Figure
S1). Two out of the seven genetic markers showed evidence of
association in the replication cohorts: rs11642873 near the IRF8
gene (lcSSc P=2.32610
212, OR=0.75 [0.69–0.81]) at the
GWAS level of significance and rs12540874 in the GRB10 gene
(lcSSc P=1.27610
26, OR=1.15 [1.09–1.22]) at the suggestive
level of significance (Figure 1, Table 1 and Table S1).
Regarding the dcSSc subtype, five non-HLA loci were found to
be associated in the GWAS cohorts (Table S2 and Figure S2).
Upon analyzing these five SNPs in the replication cohorts we
could only replicate the association of rs11171747 in the RPL41/
ESYT1 locus (overall dcSSc P=5.99610
28, OR=1.23 [1.14–
1.33]) (Figure 1, Table 1 and Table S2). However, the association
found in this locus was heterogeneous among cohorts (Breslow-
Day P=5.32610
29).
Auto-Antibodies
The observed associations in the ACA positive subgroup and
lcSSc were difficult to differentiate because of substantial overlap
between these two disease subgroups. In the GWAS cohorts, SNPs
in IL12RB2 and RUNX1 genes were identified as novel non-HLA
loci associated with SSc patients positive for ACA antibodies
(Table S3 and Figure S3). However, none of these associations
could be confirmed at the replication stage. Interestingly, the SNP
rs11047102 of the SOX5 gene, which was selected for replication
due to its association with the lcSSc subgroup in the GWAS data,
showed suggestive evidence of association with the ACA subgroup
(P=1.39610
27, OR=1.36 [1.21–1.52]) (Figure 1, Table 1 and
Table S3).
In the ATA positive subgroup, four new susceptibility loci were
identified in the GWAS data (Table S4 and Figure S4), none of
which were confirmed in the replication phase. Since the ATA
subgroup of patients has the smallest sample size, the lack of
replication in any of the non-HLA locus may be due to a lower
statistical power (Table S5).
HLA Region
The associations found in the HLA region in the GWAS data
set showed clear differences between SSc subgroups (Figure 1,
Figure 2, and Table 2). The observed effects in the lcSSc and
dcSSc subtype were similar to that of the overlapping group of
patients with ACA and ATA respectively, but less significantly.
Therefore, we focused the analysis on antibody subgroups only.
We observed independent genetic associations in the ACA
positive subgroup in the HLA region (Table 2 and Figure 1, Table
S6). The stronger independent signal was identified in the HLA-
DQB1 gene of HLA class II: SNPs rs6457617 (ACA+ P =
1.99610
236, OR=0.48 [0.42–0.54]) and rs9275390 (ACA+ P =
2.62610
254, OR=2.38 [2.13–2.67]). The TC allele combination
(both risk alleles) showed a high association in the ACA positive
subgroup (ACA+ P = 7.81610
261, OR=2.48 [2.22–2.77]), being
present in 45.3% of the ACA positive patients compared to 25.1%
of the controls (Table 3).
Regarding the ATA positive subgroup, we also observed
evidence of independent association in the HLA region (Table 2
and Figure 1, Table S7). We found three associations in the HLA
class II region: rs3129882 in HLA-DRA (ATA+ P = 1.89610
227,
OR=2.17 [1.88–2.50]), rs3129763 in the HLA-DQA1/DRB1 loci
(ATA+ P = 1.47610
211, OR=1.65 [1.42–1.91]) and four
associated SNPs in the HLA-DPA1/DPB1 region (highest associ-
ation at rs987870, ATA+ P = 2.42610
220, OR=2.09 [1.78–
2.45]). The combination of three risk alleles in the DPA1/DPB1
locus, CAC (ATA+ P = 1.27610
276, OR=8.84 [6.72–11.63]) of
the SNPs rs987870, rs3135021 and rs6901221 respectively was
present in 10.6% of the ATA positive SSc patients compared to
only 1.3% of the controls (Table 3).
In addition, in the HLA class III region, the NOTCH4 gene was
associated with the presence of ACA (rs443198, ACA+ P =
8.84610
221, OR=0.55 [0.49–0.63]) and ATA (rs9296015, ATA+
P = 1.14610
28, OR=0.54 [0.44–0.67]), independently of the
HLA class II associations (Table 2 and Tables S6, S7).
Interestingly, SNP rs9296015 had an opposite effect size in ACA
and ATA subgroup, being exclusively associated in the ATA
subgroup. These two SNPs were not in LD in Caucasian
populations either from the HapMap project (r
2=0.05 in CEU
and r
2=0.03 in TSI) or our cohorts (r
2=0.1 in the combined
cohorts, r
2=0.11 in Spanish, r
2=0.00 in German, r
2=0.00 in
Dutch and r
2=0.01 in US), pointing to independent associations
in the NOTCH4 gene with both ACA and ATA positive
subgroups. All the associations ORs found in the HLA region
were consistent among the four GWAS cohorts (Tables S8, S9).
Previously Described Genetic Associations
We wanted to investigate previously reported associations with
subphenotypes or overall disease, such as CD247, TNFSF4,
STAT4, BANK1, IRF5 and BLK in the present study’s GWAS
cohorts, to further establish them as SSc (or its subphenotypes)
susceptibility loci. Table S10 shows the analysis of the SNPs in the
previously mentioned genes which were present in our GWAS
combined panel. As expected, association previously found in
these six genes was replicated. Interestingly associations previously
described to be confined to one of the SSc subgroups were also
replicated as in the cases of TNFSF4 and lcSSc (lcSSc
P=7.70610
24, OR=1.18 [1.03–1.31]), STAT4 and lcSSc (lcSSc
P=7.70610
28, OR=1.31 [1.19–1.48]), BANK1 and dcSSc
(dcSSc P=0.0103, OR=0.85 [0.75–0.96]) and BLK and ACA+
(ACA+ P = 1.45610
24, OR=1.27 [1.12–1.44]). Furthermore
association of CD247 with SSc was more strongly represented in
the lcSSc subgroup than the others (lcSSc P = 2.66610
26,
OR=0.81 [0.75–0.89]), although evidence of association was also
Author Summary
Scleroderma or systemic sclerosis is a complex autoim-
mune disease affecting one individual of every 100,000 in
Caucasian populations. Even though current genetic
studies have led to better understanding of the patho-
genesis of the disease, much remains unknown. Sclero-
derma is a heterogeneous disease, which can be
subdivided according to different criteria, such as the
involvement of organs and the presence of specific
autoantibodies. Such subgroups present more homoge-
neous genetic groups, and some genetic associations with
these manifestations have already been described.
Through reanalysis of a genome-wide association study
data, we identify three novel genes containing genetic
variations which predispose to subphenotypes of the
disease (IRF8, GRB10, and SOX5). Also, we better charac-
terize the patterns of associated loci found in the HLA
region. Together, our findings lead to a better under-
standing of the genetic component of scleroderma.
Systemic Sclerosis Novel Genetic Associations
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IRF5 was stronger in lcSSc (lcSSc P=1.64610
210, OR=1.50
[1.32–1.69]), although association was also found in the dcSSc,
ACA+ and ATA+ subgroups.
Discussion
Systemic sclerosis (SSc) is a rare, severe, complex and
heterogeneous rheumatic disease. Multiple lines of evidence
suggest that genetic factors may underlie not only SSc suscepti-
bility but also the predisposition to develop specific clinical
phenotypes such as lcSSc, dcSSc subtypes and the presence of
SSc-specific auto-antibodies. The discovery of genetic variants
associated with specific clinical manifestations of the disease will
lead to new insights regarding pathogenesis and may open novel
avenues of therapy that can be targeted to specific subsets.
The aim of this study was to assess the genetic component
involved in four different SSc clinical and auto-antibody
Table 1. Novel non-HLA loci associated with SSc clinical and serological subtypes.
SSc
Subphenotype Chr. Gene SNP Base Pair Location Change Stage
N (case/
control)
MAF (case/
control) P{ value OR (95% CI)
lcSSc 7p12.1 GRB10 rs12540874 50,632,416 Intronic G/A GWAS 1400/5172 0.461/0.409 3.00610
26 1.23 (1.13-1.34)
Replication 1960/4971 0.416/0.395 3.07610
22 1.09 (1.01–1.18)
Combined 3360/10143 0.435/0.403 1.27610
26 1.15 (1.09–1.22)
16q24.1 IRF8 rs11642873 84,549,206 Intergenic C/A GWAS 1400/5172 0.144/0.197 1.39610
27 0.72 (0.64–0.81)
Replication 1960/4971 0.143/0.186 6.88610
26 0.78 (0.70–0.87)
Combined 3360/10143 0.144/0.192 2.32610
212 0.75 (0.69–0.81)
dcSSc 12q13.2 RPL41/ESYT1* rs11171747 54,804,675 Upstream G/T GWAS 740/5172 0.446/0.384 2.19610
26 1.31 (1.01–1.29)
Replication 959/4971 0.408/0.372 3.49610
23 1.16 (1.15–1.71)
Combined 1699/10143 0.425/0.379 5.99610
28 1.23 (1.10–1.50)
ACA+ 12p12.1 SOX5 rs11047102 23,837,413 Intronic T/C GWAS 761/5172 0.132/0.096 1.03610
25 1.47 (1.24–1.73)
Replication 1030/4971 0.123/0.102 2.91610
23 1.27 (1.09–1.48)
Combined 1791/10143 0.127/0.099 1.39610
27 1.36 (1.21–1.52)
{P values for GWAS cohorts are Mantel-Haenszel meta-analysis GC corrected according to the set l and in the replication and combined analysis Mantel-Haenszel
meta-analysis P value.
*Association in rs11171747 had a significant BD P value, thus making it heterogeneous association among populations.
doi:10.1371/journal.pgen.1002178.t001
Figure 1. New loci associated with subphenotypes of SSc. The lower part shows the Manhattan Plot with corrected P values of the GWAS
cohorts. The upper part shows the ORs and the 95% CI interval of the novel associated regions in the GWAS cohorts (HLA region, left panel) and all
cohorts (non-HLA loci, right panel) for the overall analysis and each subphenotype considered in the study. (Note: the ORs and CIs on the forest plot
do not exactly correspond to the numbers in Table 1 and Table 2. Table 1 and Table 2 shows marginal effects of these SNPs while this figure presents
ORs and CIs after the adjustment for the other SNPs claimed as independent for that phenotype).
doi:10.1371/journal.pgen.1002178.g001
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association study (GWAS) data stratified for these disease
subphenotypes, together with a large, new replication study.
We have identified an association of the NOTCH4 gene with
both ACA and ATA positive subgroups independent of the HLA
associations. This gene is located in the MHC and encodes a
transmembrane protein which plays a role in a variety of
developmental processes by controlling cell fate decisions.
Interestingly, NOTCH4 has been implicated in the pathways by
which TGF-b induces pulmonary fibrosis [24], one of the most
severe clinical manifestations of SSc [25,26]. The Notch signaling
pathway also controls key functions in vascular smooth muscle and
endothelial cells which may be particularly relevant to the
microvascular damage seen in SSc [27]. Genetic variants in
NOTCH4 also have been previously associated, independently
from HLA genes or alleles, with other autoimmune disorders like
diabetes type 1 [28], rheumatoid arthritis [29] and alopecia areata
[30,31].
Additionally, through the analysis of the largest SSc case/
control cohort reported to date we identified three new
susceptibility loci (IRF8, SOX5 and GRB10), outside the HLA/
MHC region, implicated in genetic predisposition to different SSc
subphenotypes, in addition to other suggestive loci.
Type I and II interferons (IFN) are well known immunomod-
ulators which can also regulate collagen production. Furthermore,
they are believed to play a key role in the pathogenesis of SSc and
other autoimmune diseases [32–34]. Interestingly, we found a
strong association of the IRF8 gene with the lcSSc subtype and the
ACA positive subgroup. IRF8 modulates TLR signaling and may
contribute to the crosstalk between IFN-c and TLR signal
pathways, thus acting as a link between innate and adaptive
immune responses [35]. IRF8 also has been demonstrated to be a
key factor in B cell lineage specification, commitment and
differentiation [36]. In addition, IRF8 has been associated with
another autoimmune disease, multiple sclerosis [37], although the
SNP associated with multiple sclerosis (rs17445836) was not
present in our study. Nevertheless, both variants are in medium
LD in the CEU population of the HapMap project (r
2=0.51) and
both associations have a protective OR for the minor allele;
pointing to a dependence in the associations found in these two
diseases.
The most prominent SSc specific auto-antibodies, ACA and
ATA, are associated with the lcSSc and dcSSc clinical subsets,
respectively [19]. The lcSSc subtype greatly overlaps with the
ACA positive subgroup of patients (almost all ACA positive
patients belonged to the lcSSc subtype). Similarly, the dcSSc
subtype overlaps with the ATA positive group of patients.
Therefore, it is difficult to determine whether some of the
observed associations specifically belonged to one of the four
subgroups. Such is the case of the association found with the SOX5
gene. In the GWAS data, SOX5 was associated with lcSSc as well
as with the ACA positive subgroup, although the association with
the lcSSc subtype was stronger than that in the ACA positive
subgroup. Upon completion of the replication study with the
resultant increase in statistical power, we were able to determine
that the SOX5 gene was indeed a risk factor for the ACA positive
group at the genome wide significance level, but not for lcSSc. The
SOX5 gene encodes a member of the SOX (SRY-related HMG-
box) family of transcription factors involved in the regulation of
embryonic development, in the determination of cell fate, as well
as in chondrogenesis [38].
Conversely SOX5, together with SOX6 and SOX9, can induce
many cellular types (including melanocytes and bone marrow stem
cells) into the chondrogenic pathway, leading to expression of
COL2A1 and the formation of cartilage [38,39]. As stated above,
IFN type I and II are inhibitors of collagen production and
chondrogenesis; more precisely IFN-c (type II IFN) inhibits the
COL2A1 gene which is one of the main downstream genes in the
chondrogenesis pathway [40]. Taken all together, IRF8 (part of the
interferon pathway and induced by IFN-c [41]) and SOX5 may be
affecting the formation of the extra-cellular matrix through
COL2A1 in the skin and other organs of SSc patients.
We also identified an association of the GRB10 gene with the
lcSSc subtype; GRB10 codes for an adaptor protein known to
interact with a number of tyrosine kinase receptors and signaling
molecules and has a potential role in apoptosis regulation [42].
In dcSSc patients, the only observed genome wide significant
association was with the RPL41/ESYT1 locus, although this
association was heterogeneous among the investigated populations,
probably due to lower statistical power in this smaller group. Three
genes are relevant to this locus: RPL41, a ribosomal protein not
considered to be related to the immune system; ZC3H10, a zinc
finger protein related to tumour growth; and ESYT1, a synapto-
tagmin-like protein of unknown function. Although none of these
genes has a suggestive role in the pathogenesis of SSc a priori, further
studies are needed to investigate this intriguing finding.
Since most genes in the HLA region are implicated in the
regulation of the immune system, it is not surprising that the HLA-
association with SSc is primarily related to auto-antibody
expression. We found different patterns of independent association
for the two major SSc auto-antibody subgroups across the HLA
class II region. Both genetic markers located in the HLA-DQB1
locus were associated with the presence of ACA auto-antibodies in
SSc patients. The allelic combination of these SNPs tags the
described association of HLA-DQB1*0501 with the ACA positive
subgroup of the disease [22,43]. The associations within the HLA
region in the ATA positive subgroup are more complex: SNP
rs3129763 (located near HLA-DRB1) tags the association of HLA-
DRB1*1104, which has been described to be associated with the
whole disease [22]. Furthermore, the haplotype in the HLA-DPB1
region described in Table 3, tags the HLA-DPB1*1301 also
previously described [3,22]. Interestingly, the remaining indepen-
dent association observed, rs3129882, is found within the HLA-
DRA gene, which is much less polymorphic than the other HLA
genes already mentioned; nevertheless, the association found in
this SNP is tagging through the extensive LD structure of the
MHC region the association of some aminoacidic positions in the
nearby HLA-DQB1 gene, which has not been previously reported
to be associated with the ATA positive subgroup of SSc.
In summary, taking advantage of our GWAS data and a large
replication cohort, we have identified three new non-HLA loci
associated with subphenotypes of SSc: GRB10, IRF8,a n dSOX5.I n
addition, we shed light on HLA associations with this disease,
establishing different patterns of independent association in the
ACA and ATA positive subgroups. Our findings provide evidence
for genetic heterogeneity underlying the clinical and especially
Figure 2. Manhattan plot showing the -log10 of the Mantel-Haenszel P value of all 1,112 SNPs in HLA region for the GWAS cohorts
comprising 2,296 cases and 5,171 controls. Associations for the whole SSc set are in black, while associations in ACA (760 cases) and ATA (447
cases) positive subgroups are in orange and red, respectively. Loci which were independently associated according to conditional logistic regression
analysis are highlighted in grey.
doi:10.1371/journal.pgen.1002178.g002
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reconsideration of the current classification of SSc patients; provide
insight into pathogenetic pathways differing among subphenotypes,
especially specific auto-antibody subgroups, and lead to novel
therapeutic targets for this devastating autoimmune disease.
Materials and Methods
Subjects
For the GWAS analysis, a total of 2,296 Caucasian SSc patients
and 5,171 Caucasian healthy controls were recruited through an
international collaborative effort in the United States of America
(USA), Spain, Germany and The Netherlands. The North
American cases (initial n=1,678; after applying quality control
criteria, n=1,486; 179 men, 1,307 women; mean age=54.5
(median, 55.0); SD=12.9) were recruited from May, 2001 to
December, 2008 from three U.S. sources: the Scleroderma Family
Registry and DNA Repository and the Center of Research
Translation in Scleroderma at The University of Texas (UT)
Health Science Center-Houston, The Johns Hopkins University
Medical Center and the Fred Hutchinson Cancer Research
Center, each enrolling patients from a US-wide catchment area.
The initial European SSc cases came from previously established
nationally representative collections of 380 Spanish, 288 German
and 190 Dutch patients with SSc. As control populations, healthy
unrelated individuals of Spanish (initial n=414), German (initial
n=678) and Dutch (initial n=643) origin were included in the
study as well as 3478 controls from across the US collected as non-
cancer controls for GWAS studies of breast and prostate cancers in
the Cancer Genetic Markers of Susceptibility (CGEMS) studies
[44,45] (http://cgems.cancer.gov/data/).
In the second replication phase, a large independent replication
cohort, consisting of 3,175 SSc patients and 4,971 healthy controls of
Caucasian ancestry, were collected from Belgium, Spain, The
Netherlands, Germany, Italy, Norway, Sweden, UK and the USA.
Detailson the investigated populations areprovided intheTableS11.
All cases met the American College of Rheumatology prelimi-
nary criteria for the classification of SSc [46]. Furthermore, patients
were classified according to the extent of skin involvement into
limited (lcSSc) or diffuse (dcSSc) forms [17,47]. In addition, the
presence of SSc specific auto-antibodies, anti-topoisomerase I
(ATA, Anti-Scl70) and anti-centromere (ACA) was assessed by
passive immunodiffusion against calf thymus extract (Inova
Diagnostics, San Diego, CA, USA) and indirect immunofloures-
cence ofHEp-2cells(AntibodiesInc,Davis,CA,USA),respectively,
in a total of 5,229 and 5,238 SSc patients respectively. Auto-
antibodies to RNA Polymerase III are also considered to be
characteristic of SSc, but testing for this antibody is not widely
available and since results were not known in almost two-thirds of
ourcases,this analysiswas notdone [18,19]. The distributionofSSc
patients among these disease subsets is summarized in Table S11.
Collection of blood samples and clinical information from case
and control subjects was undertaken with informed consent and
relevant ethical review board approval from each contributing
centre in accordance with the tenets of the Declaration of Helsinki.
Most of the individuals included in this study, GWAS and
replication cohorts, have been analyzed in a previous study [15]
but novel genotypes were generated in the replication cohorts for
phenotype associated SNPs found in the GWAS, expanding the
scope of the study.
SNP Selection for Replication
Our goal was to examine any novel genetic association specific
for each subset rather than overall disease. Although partial
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PLoS Genetics | www.plosgenetics.org 7 July 2011 | Volume 7 | Issue 7 | e1002178overlapping exists between lcSSc and ACA+ subgroups, and
dcSSc and ATA+ subgroups; we wanted to assess whether
association found in overlapped groups belonged to a subtype or
an auto-antibody positive group. With that purpose we selected
SNPs from the GWAS data based on the following criteria:
N First, we selected all SNPs with a P value of 1610
25 or lower
in each of the four considered SSc subgroups (i.e. lcSSc, dcSSc,
ACA+ and ATA+) of the four GWAS cohorts (i.e. US, Spain,
Netherlands and Germany).
N Since one aim of this study was to find novel genetic
associations, we then ruled out every genetic association
previously described in SSc (e.g. STAT4, IRF5 and the HLA
region).
N To select subphenotype specific signals, we excluded all SNPs
with P values of the same order of magnitude or lower in the
opposite group, i.e. lcSSc versus dcSSc and ACA-positive
versus ATA-positive.
N Finally we selected from each remaining region the best
independent association (determined by conditional logistic
regression) from the GWAS data.
This resulted in the selection of 18 non-HLA SNPs (7 for lcSSc,
5 for dcSSc, 2 for ACA+, and 4 for ATA+) as shown in Tables S1,
S2, S3, S4, corresponding to lcSSc, dcSSc, ACA and ATA positive
patients respectively.
Genotyping
The GWAS genotyping of the SSc cases and controls was
performed as follows: the Spanish SSc cases and controls together
with Dutch and German SSc cases was performed at the
Department of Medical Genetics of the University Medical Center
Utrecht (The Netherlands) using the commercial release Illumina
HumanCNV370K BeadChip, which contains 300,000 standard
SNPs with an additional 52,167 markers designed to specifically
target nearly 14,000 copy number variant regions of the genome,
for a total of over 370,000 markers. Genotype data for Dutch and
German controls were obtained from the Illumina Human 550K
BeadChipavailablefromapreviousstudy.TheSSccase groupfrom
the United States was genotyped at Boas Center for Genomics and
Human Genetics, Feinstein Institute for Medical Research, North
Shore Long Island Jewish Health System using the Illumina
Human610-Quad BeadChip. CGEMS and Illumina iControlDB
controls were genotyped on the Illumina Hap550K-BeadChip.
SNPs selected for the replication phase were genotyped in the
replication cohorts using Applied Biosystems’ TaqMan SNP assays
on ABI Prism 7900 HT real-time thermocyclers. Markers with call
rates of 95% or less were excluded, as were markers whose allele
distributions deviated strongly from Hardy-Weinberg (HW)
equilibrium in controls (P,10
23).
Data Imputation
Imputation was performed in the GWAS cohorts in order to
gain genome coverage for the SNP selection. Imputation was
performed with IMPUTE software 1.00 as previously described
[48], using as reference panels the CEU and TSI HapMap
populations. However, SNP imputation did not show any new
independent SNP associated at P,10
25 in the four subphenotypes
considered. The imputed GWAS data in the four subphenotypes is
shown in Figure S5.
Statistical Analysis
Data in the SSc GWAS cohorts was filtered as follows: Using
Plink, we identified and excluded pairs of genetically related
subjects or duplicates and excluded the genetic-pair members with
lower call rates. To identify individuals who might have non–
western European ancestry, we merged our case and control data
with the data from the HapMap Project (60 western European
(CEU), 60 Nigerian (YRI), 90 Japanese (JPT) and 90 Han Chinese
(CHB) samples). We used principal component analysis as
implemented in HelixTree (see Text S2), plotting the first two
principal components for each individual. All individuals who did
not cluster with the main CEU cluster (defined as deviating more
than 4 standard deviations from the cluster centroids) were
excluded from subsequent analyses. Additionally, we excluded
individuals with low call rates (11 individuals from the US group,
24 from the Spanish, 1 from the German and 1 from the Dutch),
relatedness (50 from the US group, 2 from the Spanish, 1 from the
German and 1 from the Dutch), non-European ancestry (42 from
the US group, 5 from the Spanish, 6 from the German and 4 from
the Dutch) and inconsistent gender (83 from the US group, 2 from
the Spanish, 2 from the German and 2 from the Dutch). Then we
filtered for SNP quality, removing SNPs with a genotyping success
call rate , 98% and those showing MAF , 1%. Deviation of the
genotype frequencies in the controls from those expected under
Hardy-Weinberg equilibrium was assessed by a x
2 test or Fisher’s
exact test when an expected cell count was , 5. SNPs strongly
deviating from Hardy-Weinberg equilibrium (P,10
25) were
Table 3. Allelic combination analysis of the SNPs which are in the same association locus within the HLA region for the ACA and
ATA positive subgroups of SSc patients.
SSc Subphenotype Locus Haplotype N (case/control)
Frequency
(case/control) P Value OR (CI 95%) SNPs
ACA HLA-DQB1 TC 761/5172 0.453/0.251 7.807610
261 2.48 (2.22–2.77) rs6457617|rs9275390
CT 761/5172 0.313/0.490 3.639610
238 0.47 (0.42–0.53) rs6457617|rs9275390
TT 761/5172 0.234/0.259 0.0353 0.87 (0.77–0.99) rs6457617|rs9275390
ATA HLA-DP CAC 447/5172 0.106/0.013 1.266610
276 8.84 (6.72–11.63) rs987870|rs3135021|rs6901221
TAC 447/5172 0.019/0.012 0.0745 1.55 (0.92–2.60) rs987870|rs3135021|rs6901221
TGC 447/5172 0.101/0.132 0.00792 0.74 (0.59–0.92) rs987870|rs3135021|rs6901221
TAA 447/5172 0.265/0.256 0.562 1.05 (0.90–1.23) rs987870|rs3135021|rs6901221
CGA 447/5172 0.148/0.127 0.0798 1.20 (0.98–1.46) rs987870|rs3135021|rs6901221
TGA 447/5172 0.361/0.460 2.137610
28 0.67 (0.58–0.77) rs987870|rs3135021|rs6901221
doi:10.1371/journal.pgen.1002178.t003
Systemic Sclerosis Novel Genetic Associations
PLoS Genetics | www.plosgenetics.org 8 July 2011 | Volume 7 | Issue 7 | e1002178eliminated from the study. For the combined analysis of the four
datasets, the same quality controls per individual and per SNP
were applied with the exception of the Hardy-Weinberg
equilibrium (HWE) requirement. The genotyping success call rate
on the merged dataset after all these quality filters were applied
was 99.83% in the GWAS cohorts.
The replication cohorts were filtered as follows: all individuals
with a SNP success call rate below 0.95 were excluded, SNPs with a
perindividualsuccesscallratebelow0.95 wereexcluded,SNPs with
a HWE comparison P value below 0.001 in controls were excluded
and SNPs with a MAF below 0.01 were also excluded. As a result,
18 SNPs selected for replication all were in HWE (P value . 0.001)
and the overall genotype successful call rate was 96.61% and all
SNPs individually had a successful call rate greater than 95%.
We performed power calculations for GWAS and replication
cohorts for the whole dataset and the clinical/auto-antibodies
subphenotypes according to Skol et al. [49] (Table S5). The
significance level for these calculations was set at 5610
-8.
x
2 tests were performed for allelic model for significant differences
between cases and controls. Derived P values for the replication
cohorts were not adjusted. All nine replication cohorts were jointly
analyzed conducting Cochran-Mantel-Haenszel (CMH) tests to
control for population differences. A threshold meta-analysis P value
of ,0.05 for the replication phasewasconsidered significant.Wealso
conducted CMH meta-analysis of all the nine replication cohorts and
the four cohorts previously included in the GWAS, considering a P
value lower than 5610
28 as significant. Furthermore, P values in the
range 5610
28 to 5610
26 were considered as suggestive associations.
In all tests, odds ratios (OR) were calculated according to Woolf’s
method.Wealso applied Breslow-Day (BD) tests forallmeta-analyses
to check for heterogeneity in association among the investigated
populations, and all associations with a P,0.05 in BD analysis were
considered heterogeneous.
Due to the partial overlapping of the lcSSc and dcSSc
subgroups with ACA+ and ATA+ subgroups, respectively, we
wanted to test whether an association found in both overlapping
groups belonged to one or the other specifically. With that
purpose, all the associations in the present study claimed to belong
to a group were tested for association in the correlated group (e.g.
ACA associations were tested in lcSSc and vice versa) to look for
the best P value. In addition, ACA and ATA hits were tested in
lcSSc-ACA- and dcSSc-ATA-, respectively, to ensure group
specific associations. Also, lcSSc and dcSSc were tested in
ACA+-non-lcSSc and ATA+-non-dcSSc with the same purpose.
To determine independent associations in the HLA region,
conditional logistic regression was carried out for all associated
SNPs in the complete SSc group and the ACA and ATA positive
subgroups. This analysis was carried out as implemented in Plink
software, conditioning each SNP association to each of the other
significantly associated (P,5610
27) SNPs in the corresponding
LD block, controlling for the presence of the four populations as
covariates. All SNPs which remained significant after conditioning
were considered independent associations. All haplotype analysis
was performed using Haploview software, defining the blocks by
confidence intervals [50]. We only analyzed haplotypes or allelic
combinations with frequencies of 1% and above.
Statistical analyses were undertaken using R (v2.6), Stata (v8),
Plink (v1.07) [51] and HelixTree’s SNP & Variation Suite (v7.3.0)
software (see Text S2).
Web Resources
Plink software:
http://pngu.mgh.harvard.edu/purcell/plink/
SVS HelixTree software:
http://www.goldenhelix.com/SNP_Variation/HelixTree/index.
html
Stata software:
http://www.stata.com/
R Statistical Package:
http://www.r-project.org/
Haploview:
http://www.broadinstitute.org/scientific-community/science/
programs/medical-and-population-genetics/haploview/haploview
Supporting Information
Figure S1 Manhattan plot and QQ plot showing the -log10 of
the Mantel-Haenszel P value of all 279,621 SNPs in the lcSSc
individuals of the GWAS cohorts comprising 1,400 cases and
5,171 controls. All P values are GC corrected, and l was 1.058.
(TIF)
Figure S2 Manhattan plot and QQ plot showing the -log10 of
the Mantel-Haenszel P value of all 279,621 SNPs in the dcSSc
individuals of the GWAS cohorts comprising 740 cases and 5,171
controls. All P values are GC corrected, and l was 1.034.
(TIF)
Figure S3 Manhattan plot and QQ plot showing the -log10 of
the Mantel-Haenszel P value of all 279,621 SNPs in the ACA
positive individuals of the GWAS cohorts comprising 761 cases
and 5,171 controls. All P values are GC corrected, and l was
1.050.
(TIF)
Figure S4 Manhattan plot and QQ plot showing the -log10 of the
Mantel-Haenszel P value of all 279,621 SNPs in the ATA positive
individuals of the GWAS cohorts comprising 447 cases and 5,171
controls. All P values are GC corrected, and l was 1.061.
(TIF)
Figure S5 Manhattan plot showing the analysis in the GWAS
cohorts imputed data. The different subphenotypes considered are
represented in different colors.
(TIF)
Table S1 Analysis for GWAS cohorts, replication cohorts and
combined analysis for all non-HLA, non-previously described
associations with lcSSc subtype of the disease. {P values for GWAS
cohorts are Mantel-Haenszel meta-analysis GC corrected accord-
ing to the set l and in the replication and combined analysis
Mantel-Haenszel meta-analysis P value. {P value for the totality of
the SSc patients, in the case of GWAS cohorts GC corrected
according to the set l, and in replication and combined analysis
Mantel-Haenszel meta-analysis P value.
(DOC)
Table S2 Analysis for GWAS cohorts, replication cohorts and
combined analysis for all non-HLA, non-previously described
associations with dcSSc subtype of the disease. {P values for
GWAS cohorts are Mantel-Haenszel meta-analysis GC corrected
according to the set l and in the replication and combined analysis
Mantel-Haenszel meta-analysis P value. {P value for the totality of
the SSc patients, in the case of GWAS cohorts GC corrected
according to the set l, and in replication and combined analysis
Mantel-Haenszel meta-analysis P value. *Association in rs11171747
had a significant BD P value, thus making them heterogenic
associations among populations.
(DOC)
Table S3 Analysis for GWAS cohorts, replication cohorts and
combined analysis for all non-HLA, non-previously described
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PLoS Genetics | www.plosgenetics.org 9 July 2011 | Volume 7 | Issue 7 | e1002178associations with ACA positive subgroup of the disease. {P values
for GWAS cohorts are Mantel-Haenszel meta-analysis GC
corrected according to the set l and in the replication and
combined analysis Mantel-Haenszel meta-analysis P value. {P
value for the totality of the SSc patients, in the case of GWAS
cohorts GC corrected according to the set l, and in replication
and combined analysis Mantel-Haenszel meta-analysis P value.
*Association in rs3790567 had a significant BD P value, thus
making them heterogeneous associations among populations.
(DOC)
Table S4 Analysis for GWAS cohorts, replication cohorts and
combined analysis for all non-HLA, non-previously described
associations with ATA positive subgroup of the disease. {P values
for GWAS cohorts are Mantel-Haenszel meta-analysis GC
corrected according to the set l and in the replication and
combined analysis Mantel-Haenszel meta-analysis P value. {P
value for the totality of the SSc patients, in the case of GWAS
cohorts GC corrected according to the set l, and in replication
and combined analysis Mantel-Haenszel meta-analysis P value.
(DOC)
Table S5 Power calculations and genomic inflation factors (l)i n
the whole SSc cohorts (GWAS and replication) and the lcSSc,
dcSSc, ACA and ATA positive subphenotypes. 5610
28 was used
as significance threshold.
(DOC)
Table S6 Conditional logistic regression analysis of all the
independently associated SNPs in the HLA region in the ACA
positive patients. {P values for Mantel-Haenszel meta-analysis GC
corrected according to the set l.
(DOC)
Table S7 Conditional logistic regression analysis of all the
independently associated SNPs in the HLA region in the ATA
positive patients. {P values for Mantel-Haenszel meta-analysis GC
corrected according to the set l.
(DOC)
Table S8 Independent associations found in the HLA region in
the ACA positive subgroup of patients in the separate four GWAS
cohorts. {Uncorrected x
2 P value of each separated cohort.
(DOC)
Table S9 Independent associations found in the HLA region in
the ATA positive subgroup of patients in the separate four GWAS
cohorts. {Uncorrected x
2 P value of each separated cohort.
(DOC)
Table S10 Previously described genetic associations with SSc
subphenotypes which were present in the present study’s GWAS
panel of SNPs. A total of 2,296 SSc cases and 5,172 controls were
included in this analysis. The SSc cases included 1,400 lcSSc
individuals, 740 dcSSc individuals, 761 ACA+ individuals and 447
ATA+ individuals. Best P value in each subgroup for each SNP is
in bold. Chr. Chromosome. { Uncorrected Mantel-Haenszel
Meta-analysis P value of the four GWAS cohorts.
(DOC)
Table S11 Composition and size of all the populations used in
the study for the considered features of the disease.
(DOC)
Text S1 Members of the Spanish Scleroderma Group.
(DOC)
Text S2 URLs. Internet Uniform Resource Locator (URL) for
each of the software packages used in this study.
(DOC)
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